A Drug to Treat Aging May Not Be a Pipe Dream (January 1, 2023)
Working at the frontier of biotechnology and medicine, our mission is to develop therapeutics to extend the period of one’s life unburdened by disease. Our initial focus is on delivering localized therapy in ophthalmologic diseases, including diabetic macular edema and age-related macular degeneration, and age-related neurologic conditions.
ANIRVAN GHOSH, PH.D.
Chief Executive Officer
LYNNE SULLIVAN
Chief Financial Officer and Head of Corporate Development
JAMIE DANANBERG, M.D.
Chief Medical Officer
PRZEMYSLAW (MIKE) SAPIEHA, PH.D.
Chief Scientist
ALEX NGUYEN
General Counsel
NATHAN GUZ, PH.D.
Vice President of Operations
ROBERT B. BHISITKUL, M.D., PH.D.
Senior Clinical Advisor
Anacor Pharmaceuticals, Inc.
MICHAEL SAMAR
Former Chief Financial Officer,
Assembly Biosciences, Inc.
NATHANIEL DAVID, PH.D.
Co-Founder,
UNITY Biotechnology
ANIRVAN GHOSH, PH.D.
Chief Executive Officer,
UNITY Biotechnology
KEITH R. LEONARD JR.
Chairman,
UNITY Biotechnology
GILMORE O’NEILL, M.B.
President and Chief Executive Officer,
Editas Medicine
MARGO ROBERTS, PH.D.
Former Chief Scientific Officer,
Lyell Immunopharma, Inc.
CAMILLE SAMUELS
Partner,
Venrock
Study Design and Execution
Strategy
A Drug to Treat Aging May Not Be a Pipe Dream (January 1, 2023)
Can Destroying Senescent Cells Treat Age-Related Disease? (March 1, 2020)
10 Breakthrough Technologies (February 26, 2020)
What If You Could Postpone The Diseases Commonly Associated With Getting Old? (February 18, 2020)
Is longevity more than a billionaire’s pipe-dream? (March 15, 2022)